Brighton Jones LLC Makes New Investment in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Brighton Jones LLC acquired a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 25,365 shares of the medical instruments supplier’s stock, valued at approximately $68,000. Brighton Jones LLC owned about 0.06% of Harvard Bioscience at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in HBIO. SG Americas Securities LLC bought a new stake in Harvard Bioscience in the 3rd quarter valued at about $36,000. Cubist Systematic Strategies LLC purchased a new position in shares of Harvard Bioscience during the second quarter worth about $40,000. Meros Investment Management LP boosted its stake in Harvard Bioscience by 1.6% in the second quarter. Meros Investment Management LP now owns 835,213 shares of the medical instruments supplier’s stock worth $2,380,000 after buying an additional 13,421 shares in the last quarter. Gabelli Funds LLC purchased a new stake in Harvard Bioscience in the second quarter worth approximately $128,000. Finally, Renaissance Technologies LLC lifted its position in Harvard Bioscience by 6.1% in the second quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock valued at $2,124,000 after purchasing an additional 42,800 shares during the last quarter. 80.87% of the stock is currently owned by institutional investors.

Harvard Bioscience Price Performance

Shares of Harvard Bioscience stock opened at $2.32 on Monday. The company has a quick ratio of 0.94, a current ratio of 2.05 and a debt-to-equity ratio of 0.48. The company has a market cap of $101.18 million, a PE ratio of -9.28 and a beta of 1.29. The business has a 50 day moving average of $2.67 and a 200 day moving average of $3.05. Harvard Bioscience, Inc. has a 52 week low of $2.30 and a 52 week high of $5.56.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.06). Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. The company had revenue of $23.10 million during the quarter, compared to analysts’ expectations of $29.91 million. As a group, equities research analysts forecast that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current year.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.